Physician profile
Anup Kumar Das
NPI 1790759082
$3,056.58
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $1,454 · 2021: $11.92 · 2023: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $1,300.00 | 2020 | |
| Merck Sharp & Dohme LLC | $165.24 | 2019-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $155.63 | 2019-2023 | |
| Amgen INC. | $154.49 | 2019 | |
| Eisai INC. | $145.86 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $140.64 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Incyte Corporation | $99.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $84.90 | 2019-2020 | |
| Pfizer INC. | $84.18 | 2019 | |
| Genentech USA, INC. | $62.44 | 2019-2023 | Gazyva, Polivy, Lunsumio |
| Janssen Biotech, INC. | $57.87 | 2019-2023 | Erleada |
| Pharmacyclics LLC, An Abbvie Company | $50.44 | 2019-2023 | Epkinly |
| Teva Pharmaceuticals USA, INC. | $47.86 | 2019 | |
| Astellas Pharma US INC | $40.35 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $38.63 | 2019 | |
| Gilead Sciences, INC. | $36.15 | 2019-2021 | |
| Seagen INC. | $35.35 | 2019 | |
| Abbvie INC. | $30.82 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $30.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.47 | 2019 | |
| Clovis Oncology, INC. | $19.26 | 2019 | |
| Lilly USA, LLC | $16.96 | 2023 | |
| Verastem, INC. | $16.84 | 2019 | |
| Mirati Therapeutics, INC. | $14.78 | 2023 | Krazati |
| Daiichi Sankyo INC. | $13.37 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.21 | 2019 | |
| Genzyme Corporation | $12.80 | 2019 | |
| Taiho Oncology, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anup Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.